Description

Vivoryon Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for Alzheimer's disease. Their primary strategy involves targeting and inhibiting the production of toxic pyroglutamate-Abeta (pGlu-Abeta). The company's lead investigational compound, PQ912, is a small molecule QC inhibitor. This candidate has successfully completed Phase IIb clinical trials for both Alzheimer's disease and cancer. In its preclinical pipeline, Vivoryon is advancing PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor, specifically for cancer treatment. Additionally, the firm is developing a monoclonal antibody designed to enhance the clearance of pGlu-Abeta. Vivoryon Therapeutics maintains a robust network of collaborations, including a research agreement with University Medical Center Schleswig-Holstein focused on cancer immunotherapy, and a partnership with Nordic Bioscience for the clinical advancement of PQ912 in Alzheimer's disease. Further alliances include a research collaboration with the Fraunhofer Institute for cell therapy and immunology, and a strategic regional licensing agreement with Simcere Pharmaceutical Group Ltd. This latter partnership aims to develop and commercialize medicines specifically targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to address Alzheimer's disease. Established in 1997, Vivoryon Therapeutics N.V. is headquartered in Halle, Germany.